AstraZeneca dumps Targacept's antidepressant TC-5214 after two more Ph III failures
This article was originally published in Scrip
Executive Summary
AstraZeneca has decided to cut its losses and drop the Phase III antidepressant candidate TC-5214 that it licensed from Targacept in December 2009.